Misplaced Pages

Motexafin lutetium

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 09:18, 13 October 2011 (Updating {{chembox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validat...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 09:18, 13 October 2011 by CheMoBot (talk | contribs) (Updating {{chembox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validat...)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Motexafin lutetium
Names
Other names Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
Identifiers
CAS Number
3D model (JSmol)
PubChem CID
SMILES
  • CC()=O.CCC1=C2C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=()C5=C/2)C(C)=C\3CCCO)=C1CC
Properties
Chemical formula C52H72LuN5O14
Molar mass 1166.136 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). checkY verify (what is  ?) Infobox references
Chemical compound

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).

It is photoactivated by 732 nm light which allows greater depth of penetration.

Clinical trials

Phase II clinical trials were in progress in 1999.

A phase I trial for prostate cancer reported in 2009.

References

  1. Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease, 2002
  2. http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
  3. Antrin® Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT, 1999
  4. Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical cancer research : an official journal of the American Association for Cancer Research. 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.
Lutetium compounds


Stub icon

This dermatologic drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: